Prosensa rises as sell-side begins to digest FDA stance on Sarepta's eteplirsen

Prosensa (RNA) rallies 11% in premarket trading.

The shares are likely responding to news that the FDA currently considers an NDA for Sarepta's (SRPT) eteplirsen to be premature.

Worth noting: The FDA's commentary on drisapersen wasn't exactly upbeat, but bad news for SRPT is considered good news for RNA as the companies are developing potentially competing DMD treatments.

The sell-side is beginning to weigh in on the eteplirsen news. Citi reportedly thinks SRPT could trade between $10-20 on the news (a pretty good bet considering it's already trading below $20 before the bell) as the company attempts to devise suitable endpoints, while Canaccord flags heightened regulatory and clinical risk.

SRPT now -54%

From other sites
Comments (1)
  • coolsun43
    , contributor
    Comments (49) | Send Message
    My bet is with rna.
    12 Nov 2013, 05:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs